Table 5.
Effect of TNFi on spinal radiographic progression according to NSAID use, with and without propensity score adjustment
| Univariate OR (95% CI) | p value | OR (95% CI) with PSa | p value | |
|---|---|---|---|---|
| Progression ≥ 2 mSASSS units | ||||
| TNFi vs. no TNFi and no NSAID | 3.33 (0.46 to 24.05) | 0.23 | 3.06 (0.27 to 34.70) | 0.37 |
| TNFi vs. no TNFi and low NSAID | 1.24 (0.46 to 3.38) | 0.67 | 1.16 (0.40 to 3.40) | 0.79 |
| TNFi vs. no TNFi and high NSAID | 0.74 (0.17 to 3.31) | 0.70 | 0.48 (0.09 to 2.48) | 0.38 |
| New syndesmophytes | ||||
| TNFi vs. no TNFi and no NSAID | 1.25 (0.14 to 10.94) | 0.84 | 2.51 (0.17 to 38.18) | 0.51 |
| TNFi vs. no TNFi and low NSAID | 1.26 (0.42 to 3.81) | 0.67 | 1.44 (0.44 to 4.70) | 0.55 |
| TNFi vs. no TNFi and high NSAID | 1.04 (0.23 to 4.69) | 0.96 | 0.84 (0.17 to 4.21) | 0.83 |
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BMI body mass index, CRP C-reactive protein, HLA-B27 Human leucocyte antigen B27, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, NSAID non-steroidal anti-inflammatory drug, PS propensity score, TNFi tumor necrosis factor inhibitor
aVariables included in PS are sex, HLA-B27, baseline CRP, BASDAI, mSASSS, smoking pack-years, BMI category, symptom duration and age of onset of symptoms